Zolmitriptan Drug Profile
What is Zolmitriptan?
Zolmitriptan is a prescription medication belonging to a class of drugs called triptans, specifically designed to treat migraine headaches. This selective serotonin receptor agonist works by targeting specific receptors in the brain to relieve migraine pain and associated symptoms. It is available in oral tablet, orally disintegrating tablet, and nasal spray formulations.
Uses
Zolmitriptan is primarily prescribed for the following conditions:
- Acute migraine treatment: The primary indication for relieving moderate to severe migraine headaches in adults
- Migraine with aura: Effective for treating migraines preceded by visual disturbances or other neurological symptoms
- Migraine without aura: Treats common migraines that occur without warning signs
- Cluster headache treatment: The nasal spray formulation is specifically approved for acute treatment of cluster headaches
- Associated migraine symptoms: Helps reduce nausea, vomiting, and sensitivity to light and sound that accompany migraines
How it works
Zolmitriptan works by binding to specific serotonin receptors (5-HT1B and 5-HT1D) in blood vessels within the brain. This action causes constriction of dilated blood vessels and reduces inflammation around nerve endings, which helps alleviate migraine pain. The medication also blocks the release of certain chemicals that contribute to migraine symptoms, providing comprehensive relief from both pain and associated symptoms.
Side effects
Common side effects include:
- Drowsiness and fatigue
- Dizziness
- Nausea
- Dry mouth
- Warm or hot sensations
- Muscle weakness
- Neck, throat, or jaw tightness
- Tingling or numbness in fingers or toes
Serious side effects requiring immediate medical attention:
- Chest pain or pressure
- Irregular heartbeat or heart palpitations
- Severe abdominal pain
- Signs of stroke (sudden weakness, vision changes, speech difficulties)
- Severe allergic reactions (difficulty breathing, swelling of face or throat)
Warnings and precautions
- Cardiovascular conditions: Should not be used by patients with coronary artery disease, uncontrolled high blood pressure, or history of heart attack or stroke
- Pregnancy and breastfeeding: Use only if potential benefits justify risks; consult healthcare provider as safety data is limited
- Liver impairment: Dosage adjustment may be necessary for patients with moderate to severe liver disease
- Overuse potential: Using triptans more than 10 days per month can lead to medication overuse headaches
- Age restrictions: Not recommended for patients over 65 or under 18 years of age due to limited safety data
Interactions
- MAO inhibitors: Can significantly increase zolmitriptan levels, potentially causing dangerous side effects
- Other triptans: Concurrent use increases risk of additive vasoconstriction and should be avoided within 24 hours
- Ergot alkaloids: Combined use may cause prolonged vasospastic reactions and is contraindicated
- SSRIs and SNRIs: May increase risk of serotonin syndrome when used together
- Cimetidine: Can increase zolmitriptan concentrations, requiring dosage adjustments
- Propranolol: May increase zolmitriptan blood levels, potentially requiring dose reduction
- St. John’s Wort: May affect serotonin levels and increase side effect risk
- Oral contraceptives: May slightly increase zolmitriptan levels but typically don’t require dose adjustment
Check interactions with the GMJ Interaction Checker
Dosage
For adults treating acute migraines, the typical starting dose is 2.5 mg taken orally, which may be repeated after 2 hours if symptoms persist, with a maximum of 10 mg in 24 hours. The orally disintegrating tablet is available in 2.5 mg and 5 mg strengths. For cluster headaches, the nasal spray formulation is typically dosed at 5 mg in one nostril, which may be repeated after 2 hours if needed, with a maximum of 10 mg in 24 hours. Patients with liver impairment may require lower starting doses. All dosages should be individualized and determined by a qualified healthcare provider based on patient response and medical history.
Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.
Cite this page
GMJ News Desk. "Zolmitriptan." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/zolmitriptan/
This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).Was this article helpful?


